David Epstein, Seagen CEO

Seagen rolls out da­ta for Ad­cetris com­bi­na­tion to treat Hodgkin lym­phoma

Seagen has long held on to Ad­cetris as one of its top-sell­ing and ex­pand­ed prod­ucts, and the lat­est da­ta for the drug, used in com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.